Advertisement

Topics

Corcept Therapeutics Company Profile

13:36 EST 16th December 2018 | BioPortfolio

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Our lead product, CORLUX, is currently in three Phase 3 clinical trials for the treatment of the psychotic features of psychotic major depression (PMD), a disorder that affects approximately three million adults in the United States each year and for which there are no FDA - approved treatments. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD. In August 2006 we announced negative top line results of one of our three Phase 3 studies. We expect to report the results the second study in September and the third in late 2006 or early 2007. Our program has been granted "fast track" status by the FDA. We have also initiated a proof-of-concept study evaluating the ability of CORLUX to mitigate weight gain associated with the use of olanzapine.

Location

149 Commonwealth Drive
Menlo Park
California
94025
United States of America

Contact

Phone: (650) 327-3270
Fax: (650) 327-3218
Email: info@corcept.com


News Articles [690 Associated News Articles listed on BioPortfolio]

Corcept Therapeutics Announces Second Quarter 2018 Financial Results and Stock Repurchase Program; Provides Clinical Update

Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effe...

Corcept Therapeutics Announces First Patient Dosed in Phase 3 Trial of Relacorilant

Corcept Therapeutics (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effe...

FDA orphan status granted to Corcept's pancreatic cancer therapy

Corcept Therapeutics' cortisol modulator relacorilant, being developed to treat patients with pancreatic cancer, received orp -More- 

Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome

Corcept Therapeutics (NASDAQ:CORT) announced today that the United States Patent and Trademark Office has given notice that it will allow a patent covering the concomitant use of Korlym® and drugs f...

Should You Buy Corcept Therapeutics Before Earnings?

Updated Investment Thesis On Corcept Therapeutics

Corcept Therapeutics - Growth Investor's Biotech Pick

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q2 2018 Results - Earnings Call Transcript

PubMed Articles [461 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [165 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sp...

Companies [1285 Associated Companies listed on BioPortfolio]

Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Our lead product, CORLUX, is curren...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Corcept Therapeutics" on BioPortfolio

We have published hundreds of Corcept Therapeutics news stories on BioPortfolio along with dozens of Corcept Therapeutics Clinical Trials and PubMed Articles about Corcept Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Corcept Therapeutics Companies in our database. You can also find out about relevant Corcept Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Bipolar Disorders
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Over half of Bipolar cases develops before the age of 25. Bipolar ...


Corporate Database Quicklinks



Searches Linking to this Company Record